Classification of Malignant Lymphomas

State of the Art
  • S. A. Pileri
  • E. Sabattini
Chapter

Abstract

The International Lymphoma Study Group (ILSG) (Table 1) was founded in 1991 by 19 experienced European and American haematopathologists with the scope to discuss and compare the problematics connected with the diagnosis and, above all, the classification of malignant lymphomas. After two meetings dealing with mantle cell lymphoma1 and Hodgkin’s disease,2 in 1993 a first draft of a new lymphoma classification was discussed: this topic was considered of primary importance by all the members due to the long lasting differences and contrasts between the American and the European schools.3–13 The ILSG reckoned that the two classifications in use (the Working Formulation and the Updated Kiel Classification) (WF, UKC)11–13 were for different reasons14–16 unsatisfactory and an update of either scheme difficult or even impossible.

Keywords

Malignant Lymphoma Mantle Cell Lymphoma Anaplastic Lymphoma Kinase Anaplastic Large Cell Lymphoma Hairy Cell Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Banks P et al. Mantle cell lymphoma: a proposai for unification of morphologic, immunologic, and molecular data. Am. J. Surg. Pathol. 1992; 16: 637–640.PubMedCrossRefGoogle Scholar
  2. 2.
    Mason DY et al. Nodular lymphocyte predominance Hodgkin’s disease. A distinct clinicopathologi-cal entity. Am. J. Surg. Pathol. 1994; 18: 526–530.PubMedCrossRefGoogle Scholar
  3. 3.
    Rappaport H. Tumors of the Hematopoietic System. In: Atlas of Tumor Pathology, Sect. 3, Fasc. 8. Washington, D.C.: Armed Forces Institute of Pathology 1966.Google Scholar
  4. 4.
    Lukes RJ, Collins RD. Immunologie characterization of human malignant lymphomas. Cancer 1974; 34: 1488–1503.PubMedCrossRefGoogle Scholar
  5. 5.
    Dorfman RF. Classification of non-Hodgkin’s lymphomas. Lancet 1974, i: 1295–1296.CrossRefGoogle Scholar
  6. 6.
    Bennett HD et al. Classification of non-Hodgkin’s lymphomas. Lancet 1974; ii: 405–406.CrossRefGoogle Scholar
  7. 7.
    Gérard-Marchant R et al. Classification of non-Hodgkin’s lymphomas. Lancet 1974; ii: 406–408.Google Scholar
  8. 8.
    Lennert K. Malignant lymphomas other than Hodgkin’s disease. New York, Heidelberg, Berlin, Springer-Verlag; 1978.CrossRefGoogle Scholar
  9. 9.
    Mathé G et al. Histological and cytological typing of neoplastic diseases of haematopoietic and lym-phoid tissues. In: International Histological Classification of Tumors, No. 14. Geneva: World Health Organization, 1976.Google Scholar
  10. 10.
    Kay HEM. Classification of non-Hodgkin’s lymphomas. Lancet 1974; ii: 586.CrossRefGoogle Scholar
  11. 11.
    Stansfeld A et al. Updated Kiel classification for lymphomas. Lancet 1988; i: 292–293.CrossRefGoogle Scholar
  12. 12.
    Lennert K, Feller AC. Histopathology of non-Hodgkin’s lymphomas (based on the Updated Kiel Classification). Berlin, Heidelberg, New York, London, Paris, Tokyo, Hong Kong, Barcellona, Budapest, Spinger-Verlag; 1992.CrossRefGoogle Scholar
  13. 13.
    Non-Hodgkin’s lymphoma pathologic classification project. National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: Summary and description of a Working Formulation for clinical usage. Cancer 1982; 49: 2112–2135.CrossRefGoogle Scholar
  14. 14.
    Isaacson PG, Norton AJ. Extranodal lymphomas. Edinburgh, London, Madrid, Melbourne, New York, Tokyo, Churchill Livingstone; 1994: 1–4.Google Scholar
  15. 15.
    Nathwani B et al. What should be the morphologic criteria for the subdivision of follicular lymphomas? Blood 1986; 68: 837–845.PubMedGoogle Scholar
  16. 16.
    Hastrup N et al. Peripheral T-cell lymphomas: an evaluation of reproducibility of the updated Kiel classification. Histopathol. 1991; 18: 99–105.CrossRefGoogle Scholar
  17. 17.
    Harris N et al. A Revised European-American Classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392.PubMedGoogle Scholar
  18. 18.
    Lippman SM et al. The prognostic significance of the immunophenotype in diffuse large-cell lymphoma: A comparative study of the T-cell and B-cell phenotype. Blood 1988; 72: 436–441.PubMedGoogle Scholar
  19. 19.
    Coiffier B et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A retrospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. Ann. Oncol. 1990; 1: 45–50.PubMedGoogle Scholar
  20. 20.
    Gerdes J et al. Prognostic relevance of tumour-cell growth fraction in malignant non-Hodgkin’s lymphomas. Lancet 1987; ii: 448–449.CrossRefGoogle Scholar
  21. 21.
    Gerdes J et al. Immunohistochemical determination of the proliferative capacity of malignant lymphomas with Ki-67 and other monoclonal antibodies. In: Cell proliferation in lymphomas. Crocker, J, Editor. Blackwell Scientific Publications, Oxford. 1993: 131–144.Google Scholar
  22. 22.
    Leoncini L et al. Correlations between apoptotic and proliferative indices in malignant non-Hodgkin’s lymphomas. Am. J. Pathol. 1993; 142: 755–763.PubMedGoogle Scholar
  23. 23.
    Pileri S et al. Apoptosis as programmed cell death (PCD): cupio dissolvi in cell life. Curr. Diagn. Pathol. 1994; 1: 48–55.CrossRefGoogle Scholar
  24. 24.
    Lo Coco F et al. Rearrangements of bcl-6 gene in diffuse large cell non-Hodgkin’s lymphoma. Blood 1994; 83: 757–759.Google Scholar
  25. 25.
    Pileri SA et al. Immunohistochemical detection of the multidrug transport protein pl70 in human normal tissue and malignant lymphomas. Histopathol. 1991; 19: 131–140.CrossRefGoogle Scholar
  26. 26.
    Mason DY et al. CD30-positive large cell lymphomas (“Ki-1 lymphoma”) are associated with a chromosomal translocation involving 5q35. Br. J. Haematol. 1990; 74: 161–168.PubMedCrossRefGoogle Scholar
  27. 27.
    Orscheschek K et al. Large-cell anaplastic lymphoma-specific translocation (t[2;5] [p23;q35]) in Hodgkin’s disease: indication of a common pathogenesis? Lancet 1995; i: 87–90.CrossRefGoogle Scholar
  28. 28.
    Bullrich F et al. Nucleophosmin (NPM) gene rearrangement in Ki-1-positive lymphomas. Cancer Res. 1994; 54: 2873–2877.PubMedGoogle Scholar
  29. 29.
    Shiota M et al. Diagnosis of t(2;5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry. Blood 1994; 84: 3648–3652.PubMedGoogle Scholar
  30. 30.
    Pulford K et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophos-min(NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 1997; 89: 1394–1404.PubMedGoogle Scholar
  31. 31.
    Pileri SA et al. Frequent Expression of the NPM-ALK Chimeric Fusion Protein in Anaplastic Large Cell Lymphoma, Lympho-Histiocytic Type. Am. J. Pathol. 1997; 150: 1207–1211.PubMedGoogle Scholar
  32. 32.
    Nakamura S et al. Anaplastic large cell lymphoma: a distinct molecular pathologic entity. A reappraisal with special reference to p80NPM/ALK expression. Am. J. Surg. Pathol. 1997; 21: 1420–1434.PubMedCrossRefGoogle Scholar
  33. 33.
    Wotherspoon AC et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; ii: 575–577.CrossRefGoogle Scholar
  34. 34.
    Isaacson PG. The MALT lymphoma concept updated. Ann. Oncol. 1995; 6: 319–329.PubMedGoogle Scholar
  35. 35.
    Zucca E et al. B-cell lymphoma of MALT type: a review with special emphasis on diagnostic and management problems of low-grade gastric tumours. Br. J. Haematol. 1998; 100: 3–14.PubMedCrossRefGoogle Scholar
  36. 36.
    Bonadonna G. Modern treatment of malignant lymphomas: a multidisclipinary approach? Ann. Oncol. 1994; 5 (suppl 2): 5–16.PubMedCrossRefGoogle Scholar
  37. 37.
    Bonadonna G. Will new treatment strategies improve the control of non-Hodgkin’s lymphomas? Curr. Opinion. Oncol. 1994; 6: 453–455.CrossRefGoogle Scholar
  38. 38.
    Pileri S, Falini B. Revised European-American Lymphoma Classification: a new approach to the study and diagnosis of malignant lymphomas. Editorial, Current Science; 1995; 7: 401–407.Google Scholar
  39. 39.
    Rosenberg SA. Classification of lymphoid neoplasms. Blood 1994; 84: 1359–1360.PubMedGoogle Scholar
  40. 40.
    Harris N et al. Lymphoma classification proposal: clarification. Blood 1995; 85: 857–860.PubMedGoogle Scholar
  41. 41.
    Stein H. Critique to the critique: Response to the editorial entitled “Classification of lymphoid neoplasms” by Dr. Saul Rosenberg which accompanied the publication of the “Revised European-American Lymphoma Classification proposal” in the September1994 issue of Blood. Ann. Oncol. 1995; 6: 109–111.PubMedGoogle Scholar
  42. 42.
    Lennert K. The proposal for a Revised European American classification—a new start of a transatlantic discussion. Histopathol. 1995; 26: 481–483.CrossRefGoogle Scholar
  43. 43.
    Meijer CJLM et al. The Revised European-American Lymphoma (REAL) Classification of non-Hodgkin’s lymphoma: a missed opportunity? Blood 1995; 85: 1971–1972.PubMedGoogle Scholar
  44. 44.
    Demeter J et al. Observations regarding hairy cell leukemia and chronic lymphocytic leukemia within the proposed new classification of lymphoid neoplasms. Blood 1995; 85: 1972–1973.PubMedGoogle Scholar
  45. 45.
    Harris NL et al. Response. Blood 1985; 85: 1973–1974.Google Scholar
  46. 46.
    Al-Saleem T. Classification of lymphoid neoplasms between the hemato-pathologists and the “common person”. Blood 1995; 85: 1974–1975.PubMedGoogle Scholar
  47. 47.
    Lister TA et al. The proposed revised European-American Classification of lymphoma. Blood 1995; 85: 1975.PubMedGoogle Scholar
  48. 48.
    O’Connor N. New classification for lymphomas. Lancet 1995; i: 1521–1522.CrossRefGoogle Scholar
  49. 49.
    Mason DY, Gatter K. Not another lymphoma classification! Br. J. Haematol. 1995; 90: 493–497.PubMedCrossRefGoogle Scholar
  50. 50.
    The non-Hodgkin’s lymphoma classification project. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin’s lymphoma. Blood 1997; 89: 3909–3918.Google Scholar
  51. 51.
    Falini B et al. Mediastinal large B-cell lymphoma: clinical and immunohistochemical findings of 18 patients treated with two different third generation regimens. Br. J. Haematol. 1995; 89: 780–789.PubMedCrossRefGoogle Scholar
  52. 52.
    Pileri S et al. Anaplastic large cell lymphoma (CD30+/KI-1+): results of the prospective clinico-pathologic study of 69 cases. Br. J. Haematol. 1994; 86: 513–523.PubMedCrossRefGoogle Scholar
  53. 53.
    Zinzani PL et al. Anaplastic large cell lymphoma (Ki-l/CD30+): clinical and prognostic evaluation of 90 adult patients. Ann. Oncol. 1996; 14: 955–962.Google Scholar
  54. 54.
    Ascani S et al. Peripheral T-cell lymphomas: Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. Annals of Oncology 1997; 8: 583–592.PubMedCrossRefGoogle Scholar
  55. 55.
    Wu CD et al. Splenic marginal zone cell lymphoma. An immunophenotypic and molecular study of five cases. Am. J. Clin. Pathol. 1996; 105: 277–285.PubMedGoogle Scholar
  56. 56.
    Solè F et al. Frequent involvement of chromosomes 1, 3, 7, and 8 in splenic marginal zone-Bcell lymphoma. Br. J. Haematol. 1997; 98: 446–449.PubMedCrossRefGoogle Scholar
  57. 57.
    Ramsey AD et al. T-cell rich B-cell lymphoma. Am. J. Surg. Pathol. 1988; 12: 433–443.CrossRefGoogle Scholar
  58. 58.
    Chittal SM et al. Large B-cell lymphoma rich in T-cells and simulating Hodgkin’s disease. Histopathol. 1991; 19: 211–220.CrossRefGoogle Scholar
  59. 59.
    Delabie J et al. Histiocyte-rich B-cell lymphoma: a distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin’s disease, paragranuloma subtype. Am. J. Surg. Pathol. 1992; 16: 37–48.PubMedCrossRefGoogle Scholar
  60. 60.
    Addis BJ, Isaacson PG. Large cell lymphoma of the mediastinum: a B cell tumour of probable thymic origin. Histopathol. 1986; 10: 379–390.CrossRefGoogle Scholar
  61. 61.
    Perrone T et al. Mediastinal diffuse large-cell lymphoma with sclerosis: a clinicopathologic study of 60 cases. Am. J. Surg. Pathol. 1986; 10: 176–191.PubMedCrossRefGoogle Scholar
  62. 62.
    Menestrina F et al. Mediastinal large-cell lymphoma with sclerosis: histopathological and immuno-histochemical study of eight cases. Histopathol. 1986; 10: 589–600.CrossRefGoogle Scholar
  63. 63.
    Fukuki M et al. An autopsy case of intravascular malignant lymphoma presenting with intracranial B-cell type malignant lymphoma. Noshuyo Byori 1996; 13: 119–125.Google Scholar
  64. 64.
    Sanna P et al. Angiotropic (intravascular) large cell 1 ymphoma: case report and short discussion of the literature. Tumori 1997; 83: 772–775.PubMedGoogle Scholar
  65. 65.
    Ascani S et al. Pyothorax-associated lymphoma: description of the first two cases detected in Italy. Ann. Oncol. 1998; in press.Google Scholar
  66. 66.
    Harris NL, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin. Diagn. Pathol. 1997; 14: 8–14.PubMedGoogle Scholar
  67. 67.
    Guinee D et al. Pulmonary lesions with features of lymphomatoid granulomatosis/angiocentric immunoproliferative lesion (LYG/AIL): evidence for Epstein-Barr virus within B lymphocytes. Mod. Pathol. 1994; 7: 151A.Google Scholar
  68. 68.
    Jaffe ES et al. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. Am. J. Surg. Pathol. 1996; 20: 103–111.PubMedCrossRefGoogle Scholar
  69. 69.
    Chan JK et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 1997: 89: 4501–4513.PubMedGoogle Scholar
  70. 70.
    Willemze R et al. EORTC Classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90: 354–371.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • S. A. Pileri
    • 1
  • E. Sabattini
    • 1
  1. 1.Service of Pathologic Anatomy/Haematopathology Unit Institute of HaematologyUniversity of BolognaItaly

Personalised recommendations